INCAGN 1876

Drug Profile

INCAGN 1876

Alternative Names: Anti-GITR-agonist-antibody-Incyte; INCAGN-1876

Latest Information Update: 29 Jun 2016

Price : $50

At a glance

  • Originator 4-Antibody; Ludwig Institute for Cancer Research
  • Developer Agenus; Ludwig Institute for Cancer Research
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action TNFRSF18 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 22 Jun 2016 Phase-I/II clinical trials in Solid tumours in USA (Parenteral) (NCT02697591)
  • 26 Feb 2016 Agenus and Incyte plan a phase I trial of INCAGN 01876 for Solid tumours (Metastatic disease, Second-line therapy or greater) (NCT02697591)
  • 21 Jan 2016 US FDA approves IND application for INCAGN 1876 in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top